FDA again declines approval of Nabrivas antibiotic for urinary tract infections Reuters Discover Thomson ReutersFinancialGovernment SolutionsLegalReuters News AgencyRisk Management SolutionsTax AccountingBlog Answers OnInnovation Thomson ReutersDirectory of sitesLoginContactSupportBusinessMarketsWorldPoliticsTVMoreUnited States Health NewsJune 20 2020 852 AM 2 days agoFDA again declines approval of Nabrivas antibiotic for urinary tract infections2 Min ReadReuters The US Food and Drug Administration declined to approve Nabriva Therapeutics Plcs antibiotic for complicated urinary tract infections citing stillunresolved manufacturing issues the biopharmaceutical company said on FridayNabriva said in a statement that the complete response letter from the FDA for the resubmission of the new drug application for Contepo for injection cited observations at the companys manufacturing partners that could not be resolved due to the FDAs inability to conduct onsite inspections because of travel restrictions from the coronavirus outbreakThe FDA did not request any new clinical data and did not raise any other concerns with regard to the safety or efficacy of Contepo Nabriva saidIn April last year the FDA had declined to approve Nabrivas antibiotic asking the company to address issues relating to manufacturing deficiencies at one of its contract manufacturersIn general previously identified product quality and facility inspection related observations at our contract manufacturing partners are required to be satisfactorily resolved before the NDA new drug application may be approved Nabriva said in the statementContepo chemically known as fosfomycin is the first intravenously administered drug from a class of antibiotics called epoxide in the United StatesFosfomycin was first discovered in 1969 and has been used to treat a variety of serious bacterial infections including complicated urinary tract infections in countries outside the United StatesThe company said it plans to request a meeting with the FDA to discuss the next steps and the FDAs plans for completing foreign facility inspectionsReporting by Kanishka Singh in Bengaluru Editing by Leslie AdlerOur StandardsThe Thomson Reuters Trust PrinciplesTrending1366 576narrowbrowserandphonemediumbrowserandportraittabletlandscapetabletmediumwidebrowserwidebrowserandlargermediumbrowserandlandscapetabletmediumwidebrowserandlargerabovephoneportraittabletandaboveaboveportraittabletlandscapetabletandabovelandscapetabletandmediumwidebrowserportraittabletandbelowlandscapetabletandbelowAppsNewslettersAdvertise with UsAdvertising GuidelinesCookiesTerms of UsePrivacyAll quotes delayed a minimum of 15 minutesSee here for a complete list of exchanges and delays 2020 ReutersAll Rights Reserved